What now for Cochlear Limited?

Cochlear has the goods, but does it have the prospects?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH), a long-time favourite of many investors, is a leading medical technology developer well known for its range of hearing implants. These implants can require quite major surgery and Cochlear remains dominant in this specialised field.

Following a 53% drop in first half 2014 earnings (compared to 2013), Cochlear's management are positive about the outlook for the company. Its arguments are compelling – new product launches gaining traction, contract wins (especially China), predicted growth in gross margins and a line of patent approvals coming through. However Cochlear does face a number of challenges, chief of which are:

Competition risk

Advanced Bionics, William Demant and Med-El are increasingly credible competitors making significant inroads into Cochlear's space. As a result Cochlear's share of the US market has fallen to 60% and indications are this trend will continue. Although management claims impending sales of the flagship Nucleus 6 and other new products will quickly reverse this, investors should be mindful that overall sales have not improved over the past three years.

Patent risks

The medical technology industry is awash with registered patents and Advanced Bionics is a very active participant in this game. Although very much a part of doing business, protecting and defending patent infringements can be costly. Cochlear recently provisioned $22.5m after being found guilty of patent infringement and this particular matter is yet to conclude.

Earnings & financial risks

Taking a pessimistic view, 2014 earnings per share may come in at $1.90, placing Cochlear ($55.05) on a multiple of 29. Although improvement can be expected in 2015, the price earnings multiple will still be above 20 – expensive even taking an optimistic view on growth prospects. It is difficult to see Cochlear doing anything more than holding its present position against rivals.

Of real concern is the high amount of intangibles on the balance sheet and the decisions to borrow funds for dividend payments over the past couple of years. This suggests a capital issue may be required in the short term to bolster the balance sheet.

Foolish takeaway

There's no doubt a logical argument can be made for investing in Cochlear – it is after all the market leader, maintains a good reputation and is well known to surgeons and the medical profession. In addition the share price has fallen by 31% over the past 12 months. However, I think none of these factors make it a worthwhile investment. Basically operating in mature markets and unable to compete effectively in developing markets, Cochlear is increasingly being pinned to the wall.

Motley Fool contributor Peter Andersen doesn't own shares in Cochlear

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »